Refining therapeutic targeting of interleukin-6 by signalling mode selectivity.

Selective targeting of IL-6 trans-signalling may improve safety and efficacy in treating inflammatory diseases by differentiating from classic signalling pathways.

• Why it matters: Current IL-6 therapies can disrupt its homeostatic functions, raising safety concerns, and a better understanding of signalling modes could enable more precise treatments.
• What they did: The authors review the molecular mechanisms of IL-6 signalling, including the roles of classic and trans-signalling, and compare global versus selective therapeutic strategies based on these pathways.
• The result: This work highlights the potential for future drug development to exploit pathway-specific modulation, enabling more targeted and safer IL-6-based therapies.